Genmab employees poised for huge windfall
Things are going well for Danish biotech company Genmab, and this developments has sent the share price significantly up. A number of employees have chosen to exercise granted warrants which could secure them millions.
BY STEFAN SINGH KAILAY
Genmab is currently booming, with rapidly increasing sales of cancer drug Darzalex and a steady stream of positive results from clinical studies with daratumumab and advances in DuoBody collaboration with Janssen. The good news also extends to the share price, which thus far in 2016 has increased by 22 percent.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Genmab prize drug shines anew
For abonnenter
Genmab boss: This surpasses my wildest dreams
For abonnenter
